HK1222563A1 - 藥物組合物、製備及其用途 - Google Patents

藥物組合物、製備及其用途

Info

Publication number
HK1222563A1
HK1222563A1 HK16110781.4A HK16110781A HK1222563A1 HK 1222563 A1 HK1222563 A1 HK 1222563A1 HK 16110781 A HK16110781 A HK 16110781A HK 1222563 A1 HK1222563 A1 HK 1222563A1
Authority
HK
Hong Kong
Prior art keywords
preparation
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
HK16110781.4A
Other languages
English (en)
Inventor
Agns Pottier
Laurent Levy
Marie-Edith Meyre
Audrey Darmon
Matthieu Germain
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of HK1222563A1 publication Critical patent/HK1222563A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
HK16110781.4A 2013-05-30 2016-09-12 藥物組合物、製備及其用途 HK1222563A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361828794P 2013-05-30 2013-05-30
EP13305712 2013-05-30
PCT/EP2014/061296 WO2014191569A1 (en) 2013-05-30 2014-05-30 Pharmaceutical composition, preparation and uses thereof

Publications (1)

Publication Number Publication Date
HK1222563A1 true HK1222563A1 (zh) 2017-07-07

Family

ID=48656009

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16110781.4A HK1222563A1 (zh) 2013-05-30 2016-09-12 藥物組合物、製備及其用途

Country Status (17)

Country Link
US (2) US10413509B2 (zh)
EP (1) EP3003288A1 (zh)
JP (1) JP6387400B2 (zh)
KR (1) KR102245421B1 (zh)
CN (2) CN105407878A (zh)
AU (1) AU2014273043B2 (zh)
BR (1) BR112015029853A2 (zh)
CA (1) CA2913023C (zh)
EA (1) EA038671B1 (zh)
HK (1) HK1222563A1 (zh)
MA (1) MA38687A1 (zh)
MX (1) MX2015016456A (zh)
NZ (1) NZ714273A (zh)
SG (1) SG11201509436TA (zh)
UA (1) UA116380C2 (zh)
WO (1) WO2014191569A1 (zh)
ZA (1) ZA201509307B (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102025743B1 (ko) 2011-12-16 2019-09-26 나노비오?스 금속성 및 산화하프늄 소재를 포함하는 나노입자, 이의 제조 및 용도
UA116380C2 (uk) 2013-05-30 2018-03-12 Нанобіотікс Посилення терапевтичної або профілактичної ефективності фармацевтичної сполуки
AR102781A1 (es) * 2014-11-25 2017-03-22 Nanobiotix Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, su preparación y sus usos
EP3229843B1 (en) * 2014-11-25 2020-01-01 Curadigm Sas Pharmaceutical composition, preparation and uses thereof
JP6835733B2 (ja) 2014-11-25 2021-02-24 キュラディグム・エスアエスＣｕｒａｄｉｇｍ Ｓａｓ 医薬組成物、その調製法及び使用
EP3236934A1 (en) * 2014-11-25 2017-11-01 Nanobiotix Pharmaceutical composition, preparation and uses thereof
EP3258917B1 (en) * 2015-02-19 2022-12-21 Carnegie Mellon University Methods to reduce toxicities and to improve bioavailabilities of nanodrugs
AR104806A1 (es) 2015-05-28 2017-08-16 Nanobiotix Nanopartículas para uso como vacuna terapéutica
CN105055447B (zh) * 2015-06-23 2018-03-13 中南大学湘雅二医院 氧化铁纳米颗粒用于制备改善厄洛替尼耐药性药物的应用
CN108969757B (zh) * 2018-07-11 2021-07-27 浙江大学 负载microRNA的氧化铈纳米复合水凝胶及制备方法和应用
CN110498607B (zh) * 2019-08-21 2022-03-08 中国科学院上海硅酸盐研究所 一种多功能钙硅基稀土掺杂的生物活性粉体及其制备方法和应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) * 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
US20030186869A1 (en) * 1990-05-14 2003-10-02 George Poiani Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
US6686332B1 (en) * 1993-10-15 2004-02-03 Xoma Corporation Method of treating depressed reticuloendothelial system function
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
AU4821697A (en) 1996-10-18 1998-05-15 Wayne State University 6',7'-dihydroxybergamottin, a cytochrome p450 ihnibitor in grapefruit juice
JPH10120597A (ja) * 1996-10-22 1998-05-12 Eiken Chem Co Ltd リンパ節高集積性コロイド粒子
ES2209184T3 (es) 1997-08-19 2004-06-16 Warner-Lambert Company Llc Composiciones que contienen bergamotina para aumentar la biodisponibilidad oral de agentes farmaceuticos.
US20040166060A1 (en) * 2000-06-16 2004-08-26 Sloan Kettering Institute For Cancer Research Liposomal encapsulation of alpha particle emittors and uses thereof
JP2004501955A (ja) * 2000-06-30 2004-01-22 アイネックス　ファーマシューティカルズ　コーポレイション リポソーム抗新生物薬剤およびその使用
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
US20050090732A1 (en) * 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
WO2005063305A1 (en) * 2003-12-22 2005-07-14 Bracco Research Sa Gas-filled microvesicle assembly for contrast imaging
AU2005220706A1 (en) * 2004-02-10 2005-09-22 Barnes-Jewish Hospital Improved efficacy and safety of targeted particulate agents with decoy systems
US20060264804A1 (en) 2005-04-07 2006-11-23 Yoram Karmon Device and kit for delivery of encapsulated substances and methods of use thereof
WO2006127962A2 (en) * 2005-05-25 2006-11-30 Becton, Dickinson And Comapny Particulate formulations for intradermal delivery of biologically active agents
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
US20090130050A1 (en) 2006-03-24 2009-05-21 Toto Ltd. Titanium Oxide Composite Particles, Dispersion Liquid Thereof, and Process for Producing Them
JP2009536151A (ja) * 2006-03-30 2009-10-08 富士フイルム株式会社 ナノ粒子
AU2007247770B2 (en) 2006-05-04 2013-07-18 Reformpharm Pty Ltd Drug release from nanoparticle-coated capsules
EP2190411A2 (en) 2007-08-21 2010-06-02 Alza Corporation Liposome compositions for in vivo administration of boronic acid compounds
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
US20100272639A1 (en) * 2007-12-21 2010-10-28 John Robert Dutcher Polysaccharide nanoparticles
EP2280601A4 (en) 2008-02-21 2012-08-29 Sequoia Pharmaceuticals Inc AMINO ACID HEMMER OF CYTOCHROM P450
WO2009142754A1 (en) * 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
EP2130553A1 (en) 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
US20130023714A1 (en) 2008-10-26 2013-01-24 Board Of Regents, The University Of Texas Systems Medical and Imaging Nanoclusters
EP2275137A1 (en) * 2009-07-10 2011-01-19 Nanobiotix Metallic nanoparticles, preparation and uses thereof
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
US9255259B2 (en) * 2010-02-09 2016-02-09 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
US8580312B2 (en) 2010-02-17 2013-11-12 National University Corporation Kobe University Radiation therapy agent
BR112012024349A2 (pt) 2010-03-26 2016-05-24 Abraxis Bioscience Llc métodos de tratamento de carcinoma hepatocelular
GB201009455D0 (en) * 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
WO2012051220A1 (en) 2010-10-11 2012-04-19 Wichita State University Composite magnetic nanoparticle drug delivery system
KR20130132475A (ko) 2010-12-17 2013-12-04 애로우헤드 리서치 코오포레이션 ｓｉＲＮＡ의 갈락토오스 클러스터-약동학적 조절제 표적 물질
US9956175B2 (en) 2011-01-31 2018-05-01 Nanobiotix Nanoparticles delivery systems, preparation and uses thereof
JP2014503575A (ja) 2011-01-31 2014-02-13 ナノビオティックス 超常磁性のナノ粒子を用いて、興味対象生成物のリポソームからの放出をモニターする方法
US20120237566A1 (en) * 2011-03-15 2012-09-20 Venture Isles, LLC Inhibiting stomach-acid release, reducing inflammation and preventing and treating cancer: compositions and methods of use
WO2013059295A2 (en) 2011-10-17 2013-04-25 Trustees Of Boston University Polymeric depots for localization of an agent to biological sites
CN102532154B (zh) 2012-01-11 2014-05-14 昆明医学院 隆萼当归线型呋喃香豆素化合物及其应用
WO2014039874A2 (en) 2012-09-07 2014-03-13 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
UA116380C2 (uk) 2013-05-30 2018-03-12 Нанобіотікс Посилення терапевтичної або профілактичної ефективності фармацевтичної сполуки
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
JP6835733B2 (ja) 2014-11-25 2021-02-24 キュラディグム・エスアエスＣｕｒａｄｉｇｍ Ｓａｓ 医薬組成物、その調製法及び使用
AR102781A1 (es) 2014-11-25 2017-03-22 Nanobiotix Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, su preparación y sus usos
EP3236934A1 (en) 2014-11-25 2017-11-01 Nanobiotix Pharmaceutical composition, preparation and uses thereof
TW201628639A (zh) 2014-11-25 2016-08-16 奈諾生技公司 醫藥組合物、其製備及其用途
EP3229843B1 (en) 2014-11-25 2020-01-01 Curadigm Sas Pharmaceutical composition, preparation and uses thereof

Also Published As

Publication number Publication date
KR20160013212A (ko) 2016-02-03
ZA201509307B (en) 2017-04-26
WO2014191569A1 (en) 2014-12-04
EA201592279A1 (ru) 2016-06-30
US11357724B2 (en) 2022-06-14
US20160184225A1 (en) 2016-06-30
MA38687A1 (fr) 2017-12-29
AU2014273043A1 (en) 2015-12-03
EA038671B1 (ru) 2021-10-01
CN112107558A (zh) 2020-12-22
NZ714273A (en) 2019-04-26
US20200009050A1 (en) 2020-01-09
CN105407878A (zh) 2016-03-16
EP3003288A1 (en) 2016-04-13
MX2015016456A (es) 2016-03-03
JP2016522833A (ja) 2016-08-04
KR102245421B1 (ko) 2021-04-29
CA2913023C (en) 2021-06-08
BR112015029853A2 (pt) 2017-07-25
US10413509B2 (en) 2019-09-17
AU2014273043B2 (en) 2019-02-07
SG11201509436TA (en) 2015-12-30
JP6387400B2 (ja) 2018-09-05
CA2913023A1 (en) 2014-12-04
UA116380C2 (uk) 2018-03-12

Similar Documents

Publication Publication Date Title
IL285390A (en) Arylquinazolines, their preparation and pharmaceutical preparations containing them
EP2815746A4 (en) SAPONIN NANOMIZELES, MANUFACTURING METHOD, APPLICATION THEREOF AND PHARMACEUTICAL COMPOSITION THEREOF
EP2968304A4 (en) 4-PHENYLPIPERIDINES, PREPARATION THEREOF AND USE THEREOF
RS59756B1 (sr) Kombinovana farmaceutska kompozicija
EP2968303A4 (en) OCTAHYDROCYCLOPENTAPYROLE AND THEIR PREPARATION AND USE
HK1221157A1 (zh) 種中藥組合物及其製劑和用途
HK1222563A1 (zh) 藥物組合物、製備及其用途
HK1220908A1 (zh) 種中藥組合物及其製劑和用途
IL252397A0 (en) Pharmaceutical preparations, their preparation and uses
HK1211021A1 (zh) -取代- -聯芳基甲基氨基- -環戊基- -嘌呤衍生物、其作為藥物的用途及藥物組合物
IL246406A0 (en) History of imidazopyrazinone, their preparation and pharmaceutical preparations containing them
IL290114A (en) Pharmaceutical preparations, their preparation and uses
EP3037099A4 (en) Pharmaceutical composition, preparation method therefor and use thereof
HK1219691A1 (zh) 醫藥組成物及其用途
SG11201601477VA (en) Pharmaceutical composition
EP2941418A4 (en) N1-CYCLIC AMIN-N5 SUBSTITUTED BIGUANIDE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH
PT3229843T (pt) Composição farmacêutica, a sua preparação e as suas utilizações
IL238851A0 (en) The history of pyrrolidine, pharmaceutical preparations and their uses
EP3078659A4 (en) 3-FURYL-2-CYANO-2-ACRYLAMIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL239873A0 (en) The history of piperidinylcarbazole, their preparation and pharmaceutical preparations containing them
IL239874B (en) History of acylguanidine, their preparation and pharmaceutical preparations containing them
HK1220143A1 (zh) 藥物組合物
HK1217670A1 (zh) 調配物、其製造方法和用途
EP2926811A4 (en) ARTEMISCULAR PHARMACEUTICAL COMPOSITION, MANUFACTURE AND USE
IL284405A (en) Pharmaceutical composition, preparation and uses thereof